Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$21.87M-$21.87MN/M vs Q2 2025 EPS Diluted-$1.52-$1.52N/M vs Q2 2025 Operating Income-$21,405,000N/M Operating Cash Flowderived-$12,845,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end